Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

22:35 EDT 22nd August 2017 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Medical News Today: Five of the best Alzheimer's blogs

Alzheimer's-related blogs may help to support people with Alzheimer's disease and their caregivers. We take a look at five of the best Alzheimer's blogs.

One Doctor's Hopeful Plan To Eradicate Alzheimer's

A new drug developed by Neurogeneticist Dr. Rudolph Tanzi could be part of a cure for Alzheimer's disease within the decade. Tanzi, who co-discovered all three early-onset familial Alzheimer’s genes...

New Drug That Could Help Eradicate Alzheimer's Is Ready For Trials

A new drug developed by Neurogeneticist Dr. Rudolph Tanzi could be part of a cure for Alzheimer's disease within the decade. Tanzi, who co-discovered all three early-onset familial Alzheimer’s genes...

Research identifies new brain death pathway in Alzheimer's disease

Alzheimer's disease tragically ravages the brains, memories and ultimately, personalities of its victims. Now affecting 5 million Americans, Alzheimer's disease is the sixth leading cause of death in ...

Alzheimer's Association calls for new strategies against dementia in Scientific American

(Alzheimer's Association) The time has come for advancing combination therapies against Alzheimer's disease, explains James A. Hendrix, Ph.D., Alzheimer's Association director of global science initia...

Surge of Alzheimer's drugs in pipeline gives hope of progress

The FDA hasn’t approved a new Alzheimer’s drug approved since 2003 -  but all this could change in the next five years according to a new analysis. A report by ResearchersAgainstAlzheimer’s (R...

Alzheimer's experts call for changes in FDA drug approval standards

(Amplify Public Affairs) Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, 'Single Endpoint for New Drug Approvals for Alzheimer's Disease,' urging ...

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer...

Matching PubMed Articles

Association of In Vivo 18FAV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegen...

The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease.

Alzheimer's disease is the most common cause of dementia. There are still no disease modifying treatments that can cure or slow disease progression. Recently, Alzheimer's disease researchers have atte...

Perspective on calcium and Alzheimer disease.

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated β-amyloid.

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study.

Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement